A carregar...
Expanding Patient Access to Investigational Drugs: Single Patient Investigational New Drug and the “Right to Try”
With drug approval times taking an average of 8 years from entry into clinical trials to full U.S. Food and Drug Administration (FDA) approval, patients with life-threatening and severely debilitating disease and no reasonable therapeutic options are advocating for expanded access (EA) to investigat...
Na minha lista:
| Publicado no: | JACC Basic Transl Sci |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Elsevier
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6059004/ https://ncbi.nlm.nih.gov/pubmed/30062214 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jacbts.2017.11.007 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|